Propagation of aggregated p53: Cross-reaction and coaggregation vs. seeding

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 8, 2015, Pages 2443-2448

  Wang, GuoZhen ^a   Fersht, Alan R ^a  

^a MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

Amyloid; Cancer; Folding; Misfolding; Protein

Indexed keywords

AMYLOID; BACTERIAL PROTEIN; PROTEIN P53; PROTEIN P63; PROTEIN P73; DNA BINDING PROTEIN; MUTANT PROTEIN; NUCLEAR PROTEIN; PROTEIN AGGREGATE; THIAZOLE DERIVATIVE; THIOFLAVINE; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

ARTICLE; BACTERIUM MUTANT; CROSS REACTION; ESCHERICHIA COLI; KINETICS; NONHUMAN; PRION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN UNFOLDING; STOICHIOMETRY; CHEMISTRY; COMPUTER SIMULATION; GENETICS; METABOLISM; MUTATION; PROTEIN MULTIMERIZATION; PROTEIN TERTIARY STRUCTURE; TIME;

COMPUTER SIMULATION; DNA-BINDING PROTEINS; KINETICS; MUTANT PROTEINS; MUTATION; NUCLEAR PROTEINS; PROTEIN AGGREGATES; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, TERTIARY; THIAZOLES; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84923666755     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1500262112     Document Type: Article

References (34)

1. Wang G, Fersht AR (2015) Mechanism of initiation of aggregation of p53 revealed by ℙ-value analysis. Proc Natl Acad Sci USA 112:2437-2442.
2. Jucker M, Walker LC (2013) Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501(7465):45-51.
3. Jarrett JT, Lansbury PT, Jr (1993) Seeding "one-dimensional crystallization" of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73(6): 1055-1058.
4. Soto C, Estrada L, Castilla J (2006) Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. Trends Biochem Sci 31(3):150-155.
5. Rochet JC, Lansbury PT, Jr (2000) Amyloid fibrillogenesis: Themes and variations. Curr Opin Struct Biol 10(1):60-68.
6. Wilcken R, Wang G, Boeckler FM, Fersht AR (2012) Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition. Proc Natl Acad Sci USA 109(34): 13584-13589.
7. Wang G, Fersht AR (2012) First-order rate-determining aggregation mechanism of p53 and its implications. Proc Natl Acad Sci USA 109(34):13590-13595.
8. Rajagopalan S, Huang F, Fersht AR (2011) Single-Molecule characterization of oligomerization kinetics and equilibria of the tumor suppressor p53. Nucleic Acids Res 39(6):2294-2303.
9. Xu J, et al. (2011) Gain of function of mutant p53 by coaggregation with multiple tumor suppressors. Nat Chem Biol 7(5):285-295.
10. Chène P, Bechter E (1999) p53 mutants without a functional tetramerisation domain are not oncogenic. J Mol Biol 286(5):1269-1274.
11. Milner J, Medcalf EA, Cook AC (1991) Tumor suppressor p53: Analysis of wild-type and mutant p53 complexes. Mol Cell Biol 11(1):12-19.
12. Joerger AC, et al. (2009) Structural evolution of p53, p63, and p73: Implication for heterotetramer formation. Proc Natl Acad Sci USA 106(42):17705-17710.
13. Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C (2001) A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol Cell Biol 21(5):1874-1887.
14. Strano S, et al. (2002) Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J Biol Chem 277(21):18817-18826.
15. Strano S, et al. (2000) Physical and functional interaction between p53 mutants and different isoforms of p73. J Biol Chem 275(38):29503-29512.
16. Natan E, Hirschberg D, Morgner N, Robinson CV, Fersht AR (2009) Ultraslow oligomerization equilibria of p53 and its implications. Proc Natl Acad Sci USA 106(34): 14327-14332.
17. Vitalis A, Pappu RV (2011) Assessing the contribution of heterogeneous distributions of oligomers to aggregation mechanisms of polyglutamine peptides. Biophys Chem 159(1):14-23.
18. Bullock AN, Henckel J, Fersht AR (2000) Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: Definition of mutant states for rescue in cancer therapy. Oncogene 19(10):1245-1256.
19. Brandt T, Kaar JL, Fersht AR, Veprintsev DB (2012) Stability of p53 homologs. PLoS ONE 7(10):e47889.
20. Tidow H, et al. (2007) Quaternary structures of tumor suppressor p53 and a specific p53 DNA complex. Proc Natl Acad Sci USA 104(30):12324-12329.
21. Natan E, et al. (2011) Interaction of the p53 DNA-binding domain with its n-terminal extension modulates the stability of the p53 tetramer. J Mol Biol 409(3):358-368.
22. Ang HC, Joerger AC, Mayer S, Fersht AR (2006) Effects of common cancer mutations on stability and DNA binding of full-length p53 compared with isolated core domains. J Biol Chem 281(31):21934-21941.
23. Nicholls CD, McLure KG, Shields MA, Lee PW (2002) Biogenesis of p53 involves cotranslational dimerization of monomers and posttranslational dimerization of dimers. Implications on the dominant negative effect. J Biol Chem 277(15):12937-12945.
24. Willis A, Jung EJ, Wakefield T, Chen X (2004) Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene 23(13):2330-2338.
25. Chène P (1998) In vitro analysis of the dominant negative effect of p53 mutants. J Mol Biol 281(2):205-209.
26. Nielsen L, et al. (2001) Effect of environmental factors on the kinetics of insulin fibril formation: Elucidation of the molecular mechanism. Biochemistry 40(20):6036-6046.
27. Woods LA, et al. (2011) Ligand binding to distinct states diverts aggregation of an amyloid-forming protein. Nat Chem Biol 7(10):730-739.
28. Colby DW, et al. (2007) Prion detection by an amyloid seeding assay. Proc Natl Acad Sci USA 104(52):20914-20919.
29. Blagosklonny MV (2000) p53 from complexity to simplicity: Mutant p53 stabilization, gain-of-function, and dominant-negative effect. FASEB J 14(13):1901-1907.
30. Willis AC, Pipes T, Zhu J, Chen X (2003) p73 can suppress the proliferation of cells that express mutant p53. Oncogene 22(35):5481-5495.
31. Di Como CJ, Gaiddon C, Prives C (1999) p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol 19(2):1438-1449.
32. Marin MC, et al. (2000) A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 25(1):47-54.
33. Li Y, Prives C (2007) Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene 26(15):2220-2225.
34. Boeckler FM, et al. (2008) Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci USA 105(30):10360-10365.